Teva Pharmaceutical Industries (NYSE:TEVA) Updates Q1 2025 Earnings Guidance

Teva Pharmaceutical Industries (NYSE:TEVA) updated its first quarter 2025 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 0.520-0.520 for the period, compared to the consensus estimate of 0.480. The company issued revenue guidance of $4.0 billion-$4.0 billion, compared to the consensus revenue estimate of $4.0 billion. Teva Pharmaceutical Industries also updated its FY 2025 guidance to 2.350-2.650 EPS.

Wall Street Analyst Weigh In

TEVA has been the subject of a number of recent research reports. Piper Sandler boosted their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, January 17th. Barclays reduced their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, January 30th. Bank of America reduced their price target on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday, March 6th. StockNews.com downgraded Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Thursday. Finally, UBS Group decreased their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $23.43.

Teva Pharmaceutical Industries Trading Down 1.1 %

Teva Pharmaceutical Industries stock opened at $15.52 on Friday. Teva Pharmaceutical Industries has a 52 week low of $12.51 and a 52 week high of $22.80. The stock has a 50-day moving average price of $17.35 and a 200 day moving average price of $18.14. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The company has a market capitalization of $17.60 billion, a price-to-earnings ratio of -10.71, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Sell-side analysts anticipate that Teva Pharmaceutical Industries will post 2.5 EPS for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.